|
Prevention of Steroid-Induced Osteoporosis in Children Clinical Trials Information presented on Clinical Trials Search isn't intended to be a substitute for proven healthcare advice, trips or treatment using a real physician. We are not docs. Always confer with your mD on Prevention of Steroid-Induced Osteoporosis in Children conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Prevention of Steroid-Induced Osteoporosis in Children Clinical research trials and Prevention of Steroid-Induced Osteoporosis in Children medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectiveness of new drugs. The intention of the studies / projects is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector corporations to detect remedies for all forms of circumstances, like Prevention of Steroid-Induced Osteoporosis in Children. Prevention of Steroid-Induced Osteoporosis in Children Clinical Trials and other clinical trials allow for volunteers to undergo healthcare treatment options before they are available to the masses. Most times the participants receive treatment for free, and every now and again they are paid for their time. Occasionally there is a cost for a Prevention of Steroid-Induced Osteoporosis in Children clinical trial. Subjects typically recieve the finest healthcare available for their Prevention of Steroid-Induced Osteoporosis in Children condition. Hazards are a reality, nonetheless, and might include more or frequent mD trips, health risks (potentially life-endangering), and/or the treatment being ineffective. Trials are federally regulated with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Prevention of Steroid-Induced Osteoporosis in Children  Prevention of Steroid-Induced Osteoporosis in Children
Prevention of Steroid-Induced Osteoporosis in Children
For Condition: Osteoporosis
Status: Not yet recruiting
Sponsor(s): National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) ,
Synopsis: The purpose of this study is to determine whether the drug pamidronate can safely and effectively improve bone mineral density in growing children who have bone disease caused by taking steroid medications. People who take steroid medications called glucocorticoids, like prednisone or dexamethasone, for long periods almost always have decreased bone density and are at increased risk of breaking a bone. Research has shown that pamidronate improves bone density in adults who take glucocorticoids. However, use of pamidronate is not approved in children because it has not been extensively tested in children. It is possible that children will have a different response or unique problems with the medication because their bones are still growing. We will assign all study participants to one of two groups. One group will recieve pamidronate intravenously (through a vein) every 3 months in addition of daily oral calcium and vitamin D and the other group will receive calcium and vitamin D. The study is scheduled to run for 36 months, with visits to the study center once every 3 months.
Details: This is a randomized study to determine whether pamidronate can safely and effectively improve bone mineral density (BMD) in children with glucocorticoid-induced osteoporosis. After we stratify participants on the basis of whether they are taking glucocorticoids for treatment of inflammatory disease or for immunosuppression following organ transplant, we will randomize them to receive daily calcium and vitamin D in addition to 30 mg/kg (1 mg/kg for weight less then 30 kg) of pamidronate in normal saline every 3 months or daily calcium and vitamin D only for 24 months, followed by a 12-month followup period off of therapy. We will measure endpoints at 24 months. The primary endpoint is lumbar spine BMD determined by DEXA. Secondary endpoints will include volumetric BMD of the spine, proximal femur BMD and volumetric BMD, total body bone mineral content (BMC), fracture incidence, bone turnover markers, and growth and skeletal changes. The study radiologist will be blinded to treatment group.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 5 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Chronic inflammatory disease or transplant recipient, currently on steroid therapy at supraphysiologic dose (greater than hydrocortisone equivalent of 15 mg/m2/day) for more than 6 months - Bone age less then 14 years in females, 16 years in males, to correspond to < 90% of peak BMD And - Presence of glucocorticoid induced bone disease defined by: - Presence of at least one atraumatic fracture (defined as fracture that occurs during activities of daily living, without a fall), or a vertebral fracture, OR - AP lumbar spine BMD (determined by DEXA) of more than 2 or more SD below the mean lumbar BMD for a healthy child of similar stature (height age). OR - A low trauma fracture (suspicious fracture - defined as a fracture the occurs with a fall from standing height or below, and not during a high velocity activity) and AP spine BMD 1.5 or more SD below the mean for height age, OR - Recent loss of BMD of greater then 3% over a 6 month or greater interval at any one of the following sites, lumbar spine, total hip or whole body (excluding head). OR - Recent increase in BMD of less then 3% over a 12 month period at all of the three sites listed above.
Total Enrollment: 40
Location and Contact Information:
Washington University Medical School-St. Louis Children's Hospital
St. Louis, Missouri, 63110
United States
Rebecca Green
Additional Information:
Study ID Numbers: NIAMS-065; K23 AR02161
Study Start Date:
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00022841
Other Osteoporosis Studies:
1. Building Better Bones in Children
2. Phase II Study of Alendronate Sodium in Children With High-Turnover Idiopathic Juvenile Osteoporosis
3. Goserelin in Preventing Ovarian Failure in Women Receiving Adjuvant Chemotherapy for Breast Cancer
4. Randomized Study of Alendronate in Adult Patients With Cystic Fibrosis Related Osteoporosis
5. Therapeutic Touch for Wrist Fractures in Postmenopausal Women
Related Studies:
Other Osteoporosis Clinical Trials
Other Missouri Clinical Trials
Other St. Louis Clinical Trials
Prevention of Steroid-Induced Osteoporosis in Children
|
|
|
|
|
|
|
|
